Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06988475 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations

Study acronym: DETERMINE
StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 16 to 17 Eligibility criteria shortened, about 196 words · Secondary endpoints: details revised at 1 of 11 entries · Study description expanded, about 2 wordsv2 Show 3 more changesShow less
    • Eligibility criteria shortened, about 196 words
    • Secondary endpoints: details revised at 1 of 11 entries
    • Study description expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Cancer Research UK
15 trials monitored
See 2 trials at risk
Gastric Cancer
1,201 trials monitored
See 59 trials at risk
Sarcoma
951 trials monitored
See 56 trials at risk
Glioma
668 trials monitored
See 40 trials at risk
This clinical trial is looking at a drug called capmatinib. Capmatinib is approved as standard of care treatment for adult patients with certain types of lung cancer. This means it has gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Capmatinib works in patients with lung cancer with a particular mutation in their cancer known as a METex14 skipping mutation. Investigators now wish to find out if it will be useful in treating patients with other cancer types which have the same mutation or other specific mutations or changes which take place in the MET gene. If the results are positive, the study team will work with the NHS and the Cancer Drugs Fund to see if these drugs can be routinely accessed for patients in the future. This trial is part of a trial programme called DETERMINE. The programme will also look at other anti-cancer drugs in the same way, through matching the drug to rare cancer types or ones with specific mutations.
Trial Details
NCT Number NCT06988475
Lead Sponsor Cancer Research UK
Collaborators: University of Birmingham, Royal Marsden NHS Foundation Trust, Novartis Pharmaceuticals, University of Manchester
Conditions Solid Tumour, Haematological Malignancy, Malignant Neoplasm, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Malignancy, Glioma +3 more
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov